Dr. Masarova on Future Research in MPNs

Video

In Partnership With:

Lucia Masarova, MD, discusses future research ​efforts in myeloproliferative neoplasms.

Lucia Masarova, MD, an assistant professor in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses future research ​efforts in myeloproliferative neoplasms (MPNs).

With multiple encouraging studies and investigational agents in the pipeline, the MPN space ​appears to be entering an exciting era, says Masarova.

Notably, the field is anticipating additional data with other JAK inhibitors ​beyond ruxolitinib (Jakafi) and fedratinib (Inrebic), ​Masrova explains.

Additionally, findings regarding targeted agents and novel combination therapies ​with JAK inhibitors ​are poised to read out at a future medical meeting, Masrova concludes.

Related Videos
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
John M. Kirkwood, MD, Distinguished Service Professor of Medicine, Sandra and Thomas Usher Professor of Medicine, Dermatology & Translational Science, coleader, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, the University of Pittsburgh
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
William B. Pearse, MD
Daniel Olson, MD
Nan Chen, MD
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center
Michael Leung, PharmD, an expert on colorectal cancer
A panel of 4 experts on colorectal cancer